Use of Oxybutynin to Treat Axillary Hyperhidrosis

Grupo de Cirurgia Vascular

Status: Completed

Conditions: Axillary Hyperhidrosis; Osmidrosis

Treatments: Drug: Oxybutynin; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01118429

0083/10

Details and patient eligibility

About

The objective of this study was to evaluate the effectiveness and patient satisfaction with the use of oxybutynin at low doses for treating axillary hyperhidrosis in a large series of patients.

Enrollment: 100 patients

Sex: All

Ages: 14 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with axillary hyperhidrosis

Exclusion criteria

• glaucoma and micturition disorders, pregnancy

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups, including a placebo group

Oxybutynin

Experimental group

Description:

Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.

Treatment:

Drug: Oxybutynin

Placebo

Placebo Comparator group

Description:

Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.

Treatment:

Drug: Placebo